Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glulisin - diabetes mellitus - narkotika anvendt i diabetes - behandling af voksne, unge og børn, seks år eller ældre med diabetes mellitus, hvor insulinbehandling er nødvendig.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - levetiracetam - oral opløsning - 100 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

biotest pharma gmbh - normalt immunglobulin, humant - infusionsvæske, opløsning - 100 g/l

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - sitagliptinmalat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - salbutamolsulfat - inhalationsspray, suspension - 100 mikrogram/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sun pharmaceutical industries europe bv - zoledronsyre, monohydrat - infusionsvæske, opløsning - 5 mg/100 ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

univar solutions bv - trientine dihydrochlorid - hepatolentikulær degeneration - andre alimentary tract and metabolism produkter, - cufence er indiceret til behandling af wilsons sygdom hos patienter, der tåler at d-penicillamin terapi, i voksne og børn i alderen 5 år eller ældre.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 500 mg